ToxSignal is the clinical toxicology newsletter from Dr. William Bundy Jr., PharmD — covering emerging drug threats, regulatory changes in drug testing, lab technology updates, and practice-relevant science. Delivered free, written for professionals.
Novel substances, adulterants, and new combinations hitting the street — covered before most clinical education catches up.
Changes to drug testing regulations, laboratory standards, federal guidance, and what they mean for your practice or program.
New research on detection windows, immunoassay gaps, confirmatory testing, and result interpretation — translated into clinical language.
Clinical toxicology moves fast — and the clinicians, drug court professionals, and legal practitioners who rely on drug testing science rarely have time to track it. Regulatory guidance changes. New substances appear in the supply. Published research takes years to reach clinical practice.
ToxSignal closes that gap. Each issue pulls together what's relevant right now — drug trends making news, regulatory changes that affect practice, and science worth knowing — and delivers it in plain clinical language, without requiring a journal subscription or a literature search.
Written by Dr. William Bundy Jr., PharmD, clinical toxicologist and drug testing specialist, and distributed free to subscribers who want to stay current without doing the hunting themselves.
Not a journal. Not a press release. Written for the people who actually use drug testing results in clinical, legal, and program settings.
Each issue covers what's most relevant — not everything that happened. The goal is to be useful in the time it takes to read, not exhaustive.
When a topic warrants more depth, issues link to Tox In Focus reference guides for the full clinical picture.
No paywall. No algorithm. Straight to your inbox when a new issue is ready.
Subscribe free and get clinical toxicology intelligence delivered to your inbox — drug trends, regulatory updates, and practice-relevant science, without the hunting.
The clinical toxicology newsletter — drug trends, regulatory updates, and practice-relevant science, delivered free.
No spam. Unsubscribe anytime.